Hjem › Diffust stort B-cellelymfom › Georgia
Kliniske studier for Diffust stort B-cellelymfom i Georgia
15 studier for Diffust stort B-cellelymfom søker deltakere på steder i Georgia.
Byer i Georgia
Offisiell studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Augusta University Georgia Cancer Center, Augusta
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University Cancer & Blood Center, LLC ( Site 0141), Athens
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Emory University Hospital, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07226843Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Atlanta Cancer Center, Newnan
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07365306Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Winship Cancer Institute of Emory University, Atlanta
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northside Hospital, Atlanta
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Winship Cancer Institute of Emory University, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Winship Cancer Institute of Emory University, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 14. apr. 2026 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. feb. 2026 · NCT05633615DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Blood and Marrow Transplant Group of Georgia, Atlanta
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. apr. 2023 · NCT04920617Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.